HAEMONETICS CORP — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Haemonetics reported Q1 FY2027 revenue of $339.4M (+5.6% YoY, +5.9% organic), with Apheresis at $191.3M (+5.3%) and MedSurg at $148.1M (+6.0%). Adjusted EPS was $1.14 (+3.6% YoY). The company raised full-year organic revenue guidance from 3-6% to 4-7%, and reported free cash flow of $39.1M, up $36.6M YoY. Operating margin (adjusted) was 23.4%, down 70 bps YoY.
Why this rating
Guidance raise and Q1 beat are solid, but modest organic growth (~6%), margin compression (70 bps), and tax headwinds temper enthusiasm. Material relative to mid-$2B market cap, but not transformational.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.